InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enables Rapid, Sustained Drop in Blood Pressure
September 17, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator of proprietary patented drug-delivery platform DehydraTECH(TM), recently released partial results from human clinical study HYPER-H21-1. The study evaluated DehydraTECH-processed cannabidiol (“CBD”) for potential application against hypertension/high blood pressure. “The partial results showed that blood pressure was reduced across both male and female volunteers; it was more pronounced […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Draws Closer to NDA Filing for DehydraTECH CBD
Lexaria just released the most important results yet from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s patented DehydraTECH(TM)-processed CBD on blood pressure Chris Bunka, Lexaria’s CEO, termed the results as “statistically significant” Participants in the study reported up to an average 23% decrease in blood pressure and a 7% drop […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment
September 16, 2021
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio –Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: The Silent Killer Making Loud Noise for Investors.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/ndmMU The market is certainly worth entering. Consider that Reportlinker.com estimates the […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Making Great Strides Toward Filing IND Application for Patented DehydraTECH(TM) Technology
September 15, 2021
Lexaria has begun the formal process of preparing an application for Investigational New Drug status for DehydraTECH(TM) and cannabidiol for hypertension The filing is being done with the assistance of an outside consultancy group, with Lexaria Bioscience designing non-clinical, clinical, and related product development required prior to the filing – all of which support Lexaria’s […]
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Throw Hat into Hypertension Ring with Proprietary Drug-Delivery System
NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Hypertension: The Silent Killer Making Loud Noise for Investors,” please […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Impressive Blood Pressure Reduction in Hypertension Clinical Trials
September 13, 2021
Lexaria Bioscience has developed a patented technology that improves the bioavailability of pharmaceuticals and therapeutics in part by bypassing first-pass-liver processing Lexaria’s patented DehydraTECH (TM) technology is undergoing human clinical trials this year to determine its effectiveness in making cannabidiol (“CBD”) effective as a means of reducing blood pressure for high blood pressure patients The […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) to Address Advances in its Bioavailability Technology DehydraTECH(TM) at Wainwright Life Sciences Conference
September 9, 2021
Drug delivery technology innovator Lexaria Bioscience is celebrating the positive outcomes of clinical testing of its trademarked DehydraTECH platform for reducing the blood stream delivery time of anti-virals, NSAIDS and potential hypertension treatments Lexaria will participate in H.C. Wainwright’s annual Global Investor Conference this month to help bring further attention to its successes The DehydraTECH […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its CEO and Chairman Chris Bunka will present at the 23rd Annual H.C. Wainwright Global Investment Conference. The event is slated to take place virtually from Sept. 13-15, 2021. According to the update, Bunka will provide an overview of […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins IND-Enabling Program for DehydraTECH-CBD for Hypertension
September 8, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced it is formally beginning the process towards an Investigational New Drug (“IND”) application filing with the Food and Drug Administration (“FDA”). The IND filing is for Lexaria’s DehydraTECH-processed cannabidiol (“DehydraTECH-CBD”) as a prospective registered pharmaceutical treatment for hypertension. The company […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) is Changing Absorption of Fat-Soluble Compounds Through Patented DehydraTECH(TM) Technology
Lexaria Bioscience Corp. and its patented DehydraTECH technology promote a more effective, less expensive form of oral drug delivery evaluated thoroughly in vivo, in vitro, and human clinical testing DehydraTECH is sub-licensed to other companies in select countries, and is in close collaboration with the largest R&D organization in Canada, the National Research Council, since […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Results of Human Clinical Study Showing Effective, Safe BP Reduction
September 7, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXX’s patented DehydraTECH(TM)-processed cannabidiol (“CBD”), demonstrates up to a 23% decrease in blood pressure when compared to placebo. According to the announcement, partial results are being released today with additional blood pressure subset analyses, sleep […]
InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Proprietary Technology Elevating Quantity of Drugs Delivered Across Blood-Brain Barrier by 1,900%
September 3, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced that a tolerability and pharmacokinetic study, performed by an independent, premier animal testing laboratory in the U.S., had demonstrated that administration of colchicine using its proprietary DehydraTECH(TM) resulted in increased delivery. “Colchicine is an approved therapeutic with anti-inflammatory effects primarily used to treat gout and cardiac conditions such […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets with Drug Delivery Technology
September 1, 2021
Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral drugs that reach the bloodstream According to a Newsfile Corp. article, this technology can be applied to rendering treatments for HIV/AIDS and other infectious diseases more effective The company also released partial results […]
InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology Is ‘Outrageously Fast’ in Oral to Bloodstream Delivery
August 27, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX) on July 22 announced it had met three primary objectives in its investigation of antiviral drug conversion process outcomes as the drugs are processed with its patented DehydraTECH(TM). “The success achieved during the company’s testing paves the way for larger analysis of the DehydraTECH-processed drugs in vivo in animals infected […]
Podcast Notes Blood Pressure Drug Delivery Trial Successes of Innovative Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology
August 24, 2021
Lexaria Bioscience is a drug delivery technology innovator whose flagship technology, DehydraTECH(TM), provides a means of enhancing substances’ delivery time to increase their effectiveness without adverse effects A new podcast by NetworkNewsAudio highlights DehydraTECH’s successes in trials that measure blood pressure reduction using DehydraTECH-enhanced CBD in comparison with generic controls The DehydraTECH technology is also […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented Technology Increasing Effectiveness and Potentially Lowering Healthcare Costs
August 18, 2021
Company’s patented DehydraTECH(TM) technology is showing the potential of reducing healthcare costs by improving oral medication administration – using capsule and pill form over injection administration Lexaria’s offering could potentially offer accelerated regulatory filing with the FDA and other regulators around the world The company sub-licenses its DehydraTECH technology for the delivery of fat-soluble active […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in PCG Report Noting Company Could Deliver for Investors
August 17, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is featured in a report issued by PCG Digital Holdings LLC, an affiliate of PCG Advisory Inc. In the report, PCG noted that “Lexaria, delivering active ingredients to patients, could deliver for investors too.” The report stated that LEXX may be poised for a surge […]
InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH Provides Potential for Significant Cost Savings to Health Care System
August 13, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced the results of its antiviral drug molecular characterization study performed by the National Research Council (“NRC”). The results confirmed that the drugs tested remained stable and did not undergo changes in chemical structure when processed with DehydraTECH. “This could preserve the ability of this drug delivery platform to […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Partial Results from Human Clinical Trial of DehydraTECH(TM)-Processed Cannabidiol for Hypertension
August 11, 2021
Clinical study HYPER-H21-1 evaluates the use of patented DehydraTECH(TM)-processed CBD for use against hypertension Hypertension is a primary or contributing factor in the death of almost 500,000 people per year, with approximately one in four adults aged 20 to 44 suffering from high blood pressure Initial results of the study show that blood pressure was […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Well Positioned to Advance Business, Further Execute on Drug-Delivery Goals
August 6, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX) is constantly collaborating with research institutions and businesses to identify new ways to innovate and improve its DehydraTECH(TM) drug-delivery technology. DehydraTECH is already being monetized through commercial use, and the company is utilizing advanced 2.0 formulations in ongoing human studies. A recent article discusses Lexaria’s move to consolidate the trading […]
First Results from Lexaria Bioscience Corp. (NASDAQ: LEXX) Study Show Marked Gains in Blood Pressure Reduction over Generic CBD Controls
Drug delivery platform developer Lexaria Bioscience has developed its patented DehydraTECH(TM) as a means of transforming pharmaceuticals that increases their bioavailability and speed of efficacy Ongoing testing of DehydraTECH in combination with cannabidiol (“CBD”) is analyzing DehydraTECH’s responsiveness to hypertension conditions that are targeted in heart disease and stroke therapies Partial results from the company’s […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hypertension Innovation
NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/dJwHD Controlling blood pressure is essential to […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment
August 4, 2021
NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Achieving Its Operational and Business Plan Objectives
August 2, 2021
Lexaria just completed dosing for its second human clinical study, HYPER-H21-2 The study sought to understand the human response to Lexaria’s DehydraTECH 2.0-enabled CBD The company also announced that its DehydraTECH-enabled consumer products are available for purchase in over 7,000 stores across the United States Lexaria also expanded its intellectual property portfolio with the allowance […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Study Results Indicating DehydraTECH-CBD Lowers Blood Pressure
July 29, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released results from its recent human clinical study focused on evaluating DehydraTECh(TM)-processed cannabidiol (“CBD”) for potential application against hypertension. The study, HYPER-H21-1, indicated a rapid, sustained drop in blood pressure with DehydraTECH-CBD as well as excellent tolerability. The partial results will be followed by […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hails Successful Testing for Effective Transformation of Antivirals for Greater Bioavailability
Lexaria Bioscience is a drug delivery technology developer advancing its IP for transforming existing consumer products and medications that may improve their availability and bioavailability The analysis of Lexaria’s DehydraTECH(TM) shows it did not create unwanted new molecular entities during the transformation process, did not inhibit the drugs’ expected antiviral functions and did increase absorption […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reaches Milestone in Human Clinical Study, Notes Growing Availability of DehydraTECH-Enabled Products
July 28, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reached a significant point in its second human clinical study of 2021: HYPER-H21-2. The company announced that dosing has been completed in the study, which was comprised of 16 human volunteers who were pre- or mildly hypertensive; each participant received three separate doses of […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes VIRAL-A20-3 Pharmacokinetic Study on DehydraTECH(TM) Enabled Colchicine
July 27, 2021
The study indicated enhanced delivery of colchicine using the company’s proprietary DehydraTECH(TM) technology Lexaria collaborates with the National Research Council (“NRC”), Canada’s leading research and technology organization The company has 20 patents granted and over 50 pending patents in over 40 countries around the world The global market for advanced drug delivery systems was valued […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures $3.8M Through Warrant Exercises
July 26, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of US$3,817,643 from the exercise of share purchase warrants. According to the update, the company issued the warrants pursuant to its January 2021 public underwritten offering. The shares and warrants issued thereunder were registered pursuant to a Form […]
Test Results Boost Lexaria Bioscience Corp. (NASDAQ: LEXX) Potential in Enhancing Antiviral Drugs
July 23, 2021
Lexaria Bioscience has completed a study conducted by Canada’s National Research Council for the use of its DehydraTECH IP with five drugs known to target the main protease associated with SARS-CoV-2 infection, including remdesivir The SARS-CoV-2 infection is the underlying force behind the COVID-19 pandemic that has killed millions of people during the past year […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of Antiviral Drug Studies, Strategy Moving Forward
July 22, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released a summary of its 2021 antiviral drug program so far this year, noting that all objectives in evaluating its proprietary DehydraTECH(TM) drug-delivery platform have been achieved. In addition, the company also discussed next steps. In short, the company stated that it has successfully tested […]
InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Significantly Enhanced Delivery of Colchicine
July 21, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. According to the update, the study demonstrated that DehydraTECH(TM)-enabled colchicine, the latest of several drugs Lexaria has successfully tested with known SARS-CoV-2 antiviral properties, benefited from the […]
InvestorNewsBreaks – Why Lexaria Bioscience Corp. (NASDAQ: LEXX) Is ‘One to Watch’
July 20, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX) is the global innovator behind the patented DehydraTECH(TM) technology. DehydraTECH increases the effectiveness of lipophilic (fat-soluble) drugs and active ingredients and improves the way active pharmaceutical ingredients enter the bloodstream. It speeds up delivery, increases bioavailability, increases brain absorption, improves drug potency, reduces drug administration cost and masks unwanted taste. […]
New Patent Expands Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Suite to 20 Granted Worldwide (First in Japan)
July 16, 2021
Drug delivery platform developer Lexaria Bioscience recently received its 20th patent — granted in Japan for beverages with lipophilic active agents The active agents include non-psychoactive cannabinoids and over-the-counter NSAIDS such as ibuprofen and aspirin that target pain and inflammation Lexaria’s DehydraTECH platform transforms drugs into a powder or liquid form that maintains the drug’s […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Completion of Antiviral Drug Molecular Characterization Study
July 15, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced the results of its antiviral drug molecular characterization study. Lexaria worked with the National Research Council (“NRC”), Canada’s premier federally funded research organization, to conduct the study. Results from the NRC confirm the study objectives, including demonstrating that the company’s proprietary DehydraTECH(TM) processing […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Commercial Success with its Drug Delivery Technology
Lexaria is making progress with research on its DehydraTECH drug delivery technology Advanced 2nd-generation DehydraTECH 2.0 formulations utilized in ongoing hypertension studies The company intends to monetize its technology for commercial use Its quest for commercial success also follows its move to delist from the Canada Securities Exchange (“CSE”) to focus on the Nasdaq listing […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Considerable IP Portfolio with Patent Protection in Japan
July 13, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced an additional expansion of its intellectual property (“IP”) portfolio with its first-ever patent granted in Japan. According to the update, “Stable ready-to-drink beverage compositions comprising lipophilic active agents” is the title of the patent that adds to the company’s considerable […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Delists from CSE to Focus Efforts on Most Effective Drug Platform Outcomes
July 12, 2021
Lexaria Bioscience is a drug bioavailability platform developer intent on providing an effective oral administration alternative to smoking that duplicates the rapid assimilation benefits of inhalation without the lung-harmful effects The company’s DehydraTECH IP is being evaluated for concentration levels, tolerability and ability to transform partner drugs to oral solutions without incidentally creating new molecular […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive Results From its Recent Animal Study on the Effectiveness of its DehydraTECH Drug Delivery Technology
July 8, 2021
Lexaria Bioscience Corp. announced positive results from its VIRAL-A20-2 study This study showed strong gains in delivery of the DehydraTECH-enabled remdesivir and ebastine among animals The success of this study shows the potential and commercial viability of Lexaria’s DehydraTECH In June 2021, Lexaria Bioscience (NASDAQ: LEXX) announced positive results from its VIRAL-A20-2 study that evaluated […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) Announces Milestone in Antiviral Delivery Platform Testing
July 6, 2021
Drug delivery platform developer Lexaria Bioscience has been testing its patented technology in conjunction with antivirals Remdesivir and Ebastine during the past year to determine the potential for enhancing their effectiveness against the COVID-19 virus Early-stage testing has determined Lexaria’s technology — DehydraTECH — did not inhibit Remdesivir and Ebastine in their use against the […]